Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 9Gemcitabine 9Cyclophosphamide 8Radiotherapy 7Carboplatin 7Paclitaxel 6Cisplatin 6Trastuzumab 5Irinotecan 5Doxorubicin 5Docetaxel 5Peripheral Blood Stem Cell Transplantation 4Filgrastim 4Capecitabine 4poly ICLC 3pazopanib 3liposomal doxorubicin 3durvalumab 3atezolizumab 3Therapeutics 3Taxes 3Surveys and Questionnaires 3Radiation 3Polymerase Chain Reaction 3Oncolytic Virotherapy 3Letrozole 3Injections 3Fulvestrant 3Fluorodeoxyglucose F18 3Flow Cytometry 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × resiquimod × Sarcoma × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡